Followers | 177 |
Posts | 24415 |
Boards Moderated | 12 |
Alias Born | 04/03/2002 |
Monday, October 31, 2005 1:36:35 PM
Industry Expert Will Guide Material Development Through Final Testing Phase; Company Developing EO Polymers for High-Speed Internet, Satellite and Military Applications
WILMINGTON, Del., Oct 31, 2005 (BUSINESS WIRE) -- PSI-TEC Corp., a wholly owned subsidiary of PSI-TEC Holdings Inc. (Pink Sheets:PTHO), a technology-based company developing chemical-based (polymer) materials for a wide roster of broadband telecommunication and military applications, announced today that it has engaged the consultancy services of former Lucent and Bell Labs veteran Dr. Gary D. Blake. PSI-TEC scientists and management expect Dr. Blake's extensive experience in modular technology to greatly accelerate the development and commercialization of PSI-TEC's breakthrough material designs.
PSI-TEC's molecularly-engineered materials are the basis of the company's revolutionary electro-optic technology product strategies. The resolution of the stability issue in material design, together with an exceptional R33 EO coefficient and high-yield material synthesis process, represents the potential to remove the final hurdle to the broad proliferation of low-cost EO polymers for numerous high-speed Internet, telecom, satellite and military applications.
"Dr. Blake's unique background and experience with modulator technology, together with his superb project management skills, is an ideal match for our emerging needs," stated Ron Genova, interim CEO of PSI-TEC Corp. "As it is imperative that we provide solid, credible performance data on our revolutionary nanotechnology-engineered EO polymer materials, we have reached the point where the collection and processing of test data must be performed using only the highest of industry-recognized practices and conditions. Dr. Blake's extensive expertise in this area will guide the project from testing to reporting and production in the coming months."
Dr. Blake's most recent accomplishments come from Lucent Technologies/Bell Labs where he supervised the design, fabrication, testing, qualification and production ramp of Lucent's highly successful lithium niobate modulator technology platform.
"Drawing on his proven success with test requirements, equipment, procedures and practices, Dr. Blake will work closely with Dr. C.C. Teng, PSI-TEC's distinguished member of technical staff, to establish testing facilities for material evaluations," said Frederick Goetz, Jr., president of PSI-TEC Corp. "The collaborative test facility effort by Dr. Blake and Dr. Teng is critical to confirming the soundness of our Aromatic Gain theory approach and will play an instrumental role in the future development and testing of waveguides, high-speed Mach-Zehnder modulators, and other devices created from our OE polymer material platform."
Company sources believe mu-beta and initial R33 EO coefficient test data (figures of merit for high-speed non-linear optic NLO polymer performance) could be released before the end of this year on the company's first commercial nanotechnology-engineered EO polymer molecule. The company projects definitive material stability testing will be completed shortly thereafter on waveguide structures.
About PSI-TEC
PSI-TEC Corp. is a developmental stage company that engineers next-generation electro-optic (EO) plastics for future applications vital to modern commerce, homeland security and medical technology. PSI-TEC's proprietary electro-optic plastics are produced at the molecular level for superior performance, stability and cost-efficiency and are expected to replace more expensive, lower-performance materials used in fiber-optic ground, wireless and satellite communication networks. For more information regarding PSI-TEC's mission, management and technology, visit the company at www.psiteccorp.com.
Safe Harbor Statement
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the company's control.
SOURCE: PSI-TEC Corp.
Thinkbig Media for PSI-TEC Corp.
Carrie Altuvilla, 949-330-6055
Mobile: 661-312-6952
carrie@thinkbigmedia.com
Copyright Business Wire 2005
Recent LU News
- Lufax Announces Annual General Meeting on May 30, 2024 and Filing of Its Annual Report on Form 20-F • PR Newswire (US) • 04/23/2024 01:05:00 PM
- Lufax Reports First Quarter 2024 Financial Results • PR Newswire (US) • 04/22/2024 09:30:00 PM
- Lufax to Announce First Quarter 2024 Financial Results on April 22, 2024 • PR Newswire (US) • 04/16/2024 11:00:00 AM
- U.S. Index Futures Rise as Fed’s Dovish Outlook Spurs Positive Investor Sentiment; Oil Prices See Minor Declines • IH Market News • 03/21/2024 11:26:38 AM
- Lufax Reports Fourth Quarter and Full Year 2023 Financial Results • PR Newswire (US) • 03/21/2024 08:30:00 AM
- Lufax to Announce Fourth Quarter and Fiscal Year 2023 Financial Results on March 21, 2024 • PR Newswire (US) • 03/12/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/11/2024 08:01:49 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2024 09:04:54 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 11:08:49 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/06/2024 09:02:03 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/05/2024 12:03:25 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/05/2024 09:03:03 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/15/2023 10:00:56 PM
- Lufax Announces Receipt of Notice Regarding NYSE Continued Listing Standards and Effectiveness of its ADS Ratio Change • PR Newswire (US) • 12/15/2023 09:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/05/2023 12:48:25 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/21/2023 11:04:57 AM
- Lufax Holding Ltd Announces Plan to Implement ADS Ratio Change • PR Newswire (US) • 11/20/2023 09:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/14/2023 11:12:56 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/14/2023 11:08:57 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/14/2023 11:07:27 AM
- Lufax Reports Third Quarter 2023 Financial Results • PR Newswire (US) • 11/13/2023 09:30:00 PM
- Lufax to Announce Third Quarter 2023 Financial Results on November 13, 2023 • PR Newswire (US) • 11/07/2023 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/03/2023 08:02:27 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/01/2023 10:06:28 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/10/2023 10:07:57 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM